Note: This article does not constitute any investment advice or recommendations; please refer to official/company announcements for accuracy. This article only provides an introduction to medical and health-related drugs, not a recommendation of treatment plans (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
December 17, 2025, T-CURX announced today the successful completion of its Series A first closing with $20 million in funding. This round of financing was jointly participated by investors from Europe and Asia. The proceeds will be used to accelerate the clinical development of the company’s CAR-T therapies based on its non-viral technology platform in the fields of acute myeloid leukemia (AML) and solid tumors, and further advance its proprietary in vivo CAR-T technology platform.This round of financing was led by BiomedVC, with joint investments from professional institutions such as Bayern Kapital, HighLight Capital (Hillhouse Capital), and i&iBio Fund. Existing investors also continued to participate.T-CURX Co-Founder and CEO, Dr. Ulf Grawunder, stated: "I am deeply honored that T-CURX has attracted an international group of investors led by BiomedVC with strong industry backgrounds. This financing will provide funding support for T-CURX's non-clinical and clinical CAR-T technologies and pipeline projects. It not only validates the high quality of the data demonstrated by T-CURX but also highlights the tremendous potential of our non-viral CAR-T pipelines targeting novel antigens in AML, CLL, and solid tumors. Furthermore, this successful financing further underscores the value of our unique technological approach: combining non-viral CAR vectors with LNP technology to create a more cost-effective and scalable in vivo CAR-T generation platform, aiming to make CAR-T therapy accessible to a broader global patient population."T-CURX is a German biotechnology company founded in 2017, headquartered in Würzburg. The company is committed to developing the next generation of CAR-T cell therapies by leveraging its cost-effective and scalable non-viral CAR-T cell technology to benefit more cancer patients in urgent need of efficient treatment. T-CURX was incubated from the laboratory of Professor Michael Hudecek of the University of Würzburg, a co-founder of the company, and is led by experienced serial entrepreneur Dr. Ulf Grawunder, who serves as CEO. The company relies on a series of proprietary technologies, including the use of the non-viral Sleeping Beauty transposon system, to achieve efficient and scalable CAR-T cell production.Reference: Company Announcement
Mastering CAR-T Therapy, Stem Cell Therapy, Gene
Therapy,Comprehensive Information on Oncolytic Viruses and Nucleic Acid Drugs
